Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

被引：227

作者：

Davids, Matthew S. ^{[1
]}

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 25期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; BCL-2 ANTISENSE OLIGONUCLEOTIDE; ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-737; PHASE-I; CHROMOSOME-TRANSLOCATION; MITOCHONDRIAL-MEMBRANE; OBLIMERSEN SODIUM; CYTOCHROME-C; OBATOCLAX MESYLATE;

D O I：

10.1200/JCO.2011.37.0981

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago. In the intervening decades, the way the BCL-2 family controls commitment to programmed cell death has been greatly elucidated. Several drugs directed at inhibiting BCL-2 and related antiapoptotic proteins have been tested clinically, with some showing considerable promise, particularly in lymphoid malignancies. A better understanding of the BCL-2 family has also provided insight into how conventional chemotherapy selectively kills cancer cells and why some cancers are more chemosensitive than others. Further exploitation of our understanding of the BCL-2 family promises to offer improved predictive biomarkers for oncologists and improved therapies for patients with cancer. J Clin Oncol 30: 3127-3135. (C) 2012 by American Society of Clinical Oncology

引用

页码：3127 / 3135

页数：9

共 72 条

[71] Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins
Zhai, D.
Jin, C.
Satterthwait, A. C.
Reed, J. C.
[J]. CELL DEATH AND DIFFERENTIATION, 2006, 13 (08) : 1419 - 1421
[72] Bcl-2 family proteins are essential for platelet survival
Zhang, H.
Nimmer, P. M.
Tahir, S. K.
Chen, J.
Fryer, R. M.
Hahn, K. R.
Iciek, L. A.
Morgan, S. J.
Nasarre, M. C.
Nelson, R.
Preusser, L. C.
Reinhart, G. A.
Smith, M. L.
Rosenberg, S. H.
Elmore, S. W.
Tse, C.
[J]. CELL DEATH AND DIFFERENTIATION, 2007, 14 (05) : 943 - 951

← 1 2 3 4 5 6 7 8 →